Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Latest Soft tissue sarcoma Stories

2008-07-31 09:01:26

SALT LAKE CITY, July 31, 2008 (PRIME NEWSWIRE) -- BSD Medical Corporation (Nasdaq:BSDM) today announced that the company's most advanced cancer treatment system, the BSD-2000/3D/MR, has been adapted to treat children with cancer, as well as adults. To accommodate the treatment of children, BSD Medical has developed sophisticated treatment applicators that are specifically sized for small and medium-sized children, and that are capable of delivering pediatric cancer therapy during simultaneous...

2008-07-08 09:01:11

ImClone Systems has announced that a Phase II clinical trial of IMC-A12, the company's fully human, IgG1 anti-insulin-like growth factor-1 receptor monoclonal antibody, in adolescents and adult patients with several types of soft tissue sarcoma has opened for patient enrollment. This multinational Phase II study will evaluate the efficacy of IMC-A12 in adult and adolescent patients with several types of previously treated, advanced or metastatic soft tissue sarcoma, which were selected...

2008-07-07 09:01:02

ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that a Phase 2 clinical trial of IMC-A12, ImClone's fully human, IgG1 anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody, in adolescents and adult patients with several types of soft tissue sarcoma has opened for patient enrollment. "This Phase 2 study of IMC-A12 builds on a biological rationale that suggests that the...

2008-06-18 09:01:17

BSD Medical Corp. (NASDAQ: BSDM) today reported that in the Annals of Oncology (Volume 19, Supplement 2, 2008), the European Society for Medical Oncology (ESMO) Clinical Treatment Guideline Working Group has published its relevant clinical treatment guidelines under "Soft tissue sarcomas: ESMO Clinical Recommendations for diagnosis, treatment and follow-up." The guidelines highlight hyperthermia therapy as a treatment option for several types of soft tissue sarcomas. The ESMO Guidelines...

2007-06-24 21:00:10

By JESSICA FARGEN At one of the country's most esteemed cancer centers, where great phycisians combat the rarest diseases, Dr. Monica Bertagnolli takes the cases no one else can. Colleagues say her surgical skills save patients who have few places to turn to rid their bodies of stubborn and deadly cancers. And her prowess in the lab has influenced the drugs that tens of thousands take to prevent colon cancer. "I would consider her one of our superstars," said Dr. Michael Zinner, chief...

2007-04-14 03:00:12

By Macarenco, Ricardo S; Ellinger, Fred; Oliveira, Andre M Context.-Perineuriomas are benign peripheral nerve sheath neoplasms composed of perineurial cells with characteristic immunohistochemical and ultrastructural features. They have been traditionally classified into two main types according to their location-intraneural and extraneural- and overlap histologically with many other tumors, which may be diagnostically challenging to general surgical pathologists. Objective.-To review the...

2006-02-03 10:15:00

By Anne Harding NEW YORK -- Children who survive cancer face a four-fold increased risk of developing cancers as adults, and these malignancies appear at an earlier-than-normal age, a new study shows. But careful screening -- as well as awareness of potential early symptoms -- can help ensure that disease is caught early, when it's much easier to treat, Dr. Nina S. Kadan-Lottick told Reuters Health in an interview. "Most of these subsequent cancers are amenable to screening and...

2005-11-03 14:47:04

Paris, France, Thursday 3 November 2005 - Updated results from a Phase III trial presented at the 13th European Cancer Conference (ECCO) show that sunitinib (SU11248) prolongs both progression-free and overall survival in patients with progressive metastatic and/or unresectable GIST whose disease has failed to respond to the standard therapy - imatinib mesylate. This study was a double-blind, placebo-controlled, international, multicentre, Phase III trial involving 312 patients with GIST...